Grace Therapeutics (GRCE) Income from Continuing Operations (2019 - 2026)
Grace Therapeutics (GRCE) posted Income from Continuing Operations of 1178000.0 for Q1 2026, up 49.11% sequentially from 2315000.0 in Q4 2025, and down 1098.31% YoY from 118000.0 in Q1 2025.
Grace Therapeutics (GRCE) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Grace Therapeutics has reported Income from Continuing Operations for 8 years, with the latest figure at 1178000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 1098.31% year-over-year to 1178000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7793000.0 (up 22.73% YoY) and the FY2026 annual result came in at 7793000.0, up 22.73% from the prior year.
- Income from Continuing Operations advanced to 1178000.0 in Q1 2026 per GRCE's latest filing, from 2315000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 118000.0 in Q1 2025 and troughed at 38629000.0 in Q1 2023.
- A 5-year average of 5057176.47 and a median of 3362000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations slumped 2072.61% in 2023, then jumped 102.53% in 2025.
- Over 5 years, Income from Continuing Operations stood at 3889000.0 in 2022, then soared by 38.52% to 2391000.0 in 2023, then sank by 73.78% to 4155000.0 in 2024, then surged by 44.28% to 2315000.0 in 2025, then jumped by 49.11% to 1178000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1178000.0, 2315000.0, and 938000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | -15.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.79 Mn |
| Mar 31, 2026 | -1.18 Mn |
| Dec 31, 2025 | -2.32 Mn |
| Sep 30, 2025 | -938,000.00 |
| Jun 30, 2025 | -3.36 Mn |
| Mar 31, 2025 | 118,000.00 |
| Dec 31, 2024 | -4.16 Mn |
| Sep 30, 2024 | -3.43 Mn |
| Jun 30, 2024 | -2.62 Mn |
| Mar 31, 2024 | -4.66 Mn |
| Dec 31, 2023 | -2.39 Mn |
| Sep 30, 2023 | -3.27 Mn |
| Jun 30, 2023 | -4.02 Mn |
| Mar 31, 2023 | -38.63 Mn |
| Dec 31, 2022 | -3.89 Mn |
| Sep 30, 2022 | -4.93 Mn |
| Jun 30, 2022 | -4.52 Mn |
| Mar 31, 2022 | -1.78 Mn |
| Dec 31, 2021 | -3.78 Mn |
| Sep 30, 2021 | 981,000.00 |